In last trading session, Emergent Biosolutions Inc (NYSE:EBS) saw 1.52 million shares changing hands with its beta currently measuring 2.10. Company’s recent per share price level of $6.15 trading at $0.62 or 11.21% at ring of the bell on the day assigns it a market valuation of $334.17M. That closing price of EBS’s stock is at a discount of -145.53% from its 52-week high price of $15.10 and is indicating a premium of 70.41% from its 52-week low price of $1.82. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.74 million shares which gives us an average trading volume of 1.19 million if we extend that period to 3-months.
For Emergent Biosolutions Inc (EBS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 1.14 in the current quarter.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Upright in the green during last session for gaining 11.21%, in the last five days EBS remained trading in the green while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $6.15 price level, adding 3.3% to its value on the day. Emergent Biosolutions Inc’s shares saw a change of -35.67% in year-to-date performance and have moved 6.03% in past 5-day. Emergent Biosolutions Inc (NYSE:EBS) showed a performance of -39.17% in past 30-days. Number of shares sold short was 8.14 million shares which calculate 7.88 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 51.5 to the stock, which implies a rise of 88.06% to its current value. Analysts have been projecting 38 as a low price target for the stock while placing it at a high target of 65. It follows that stock’s current price would drop -517.89% in reaching the projected high whereas dropping to the targeted low would mean a loss of -517.89% for stock’s current value.
Emergent Biosolutions Inc (EBS) estimates and forecasts
This year revenue growth is estimated to fall -20.95% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 218.5M for the same. And 2 analysts are in estimates of company making revenue of 194M in the next quarter. Company posted 300.4M and 254.7M of sales in current and next quarters respectively a year earlier.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Insiders are in possession of 2.09% of company’s total shares while institution are holding 64.58 percent of that, with stock having share float percentage of 65.96%. Investors also watch the number of corporate investors in a company very closely, which is 64.58% institutions for Emergent Biosolutions Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at EBS for having 3.84 million shares of worth $26.18 million. And as of 2024-06-30, it was holding 7.3551 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 3.67 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0234 of outstanding shares, having a total worth of $25.0 million.
On the other hand, Avantis U.S. Small Cap Value ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.79 shares of worth $10.98 million or 3.29% of the total outstanding shares. The later fund manager was in possession of 1.65 shares on Dec 31, 2024 , making its stake of worth around $10.14 million in the company or a holder of 3.03% of company’s stock.
